Combining Anti-Angiogenic Therapy and Immune Checkpoint Inhibitors for Digestive System Cancers
Author Information
Author(s): Xu Qinlan, Dong Shao
Primary Institution: The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China
Hypothesis
Can the combination of anti-angiogenic therapy and immune checkpoint inhibitors improve treatment outcomes for digestive system cancers?
Conclusion
The combination of anti-angiogenic therapy and immune checkpoint inhibitors shows promise in enhancing treatment efficacy and improving patient outcomes in digestive system cancers.
Supporting Evidence
- The combination of anti-angiogenic therapy and immune checkpoint inhibitors can enhance anti-tumor immunity.
- Clinical trials have shown improved patient outcomes when these therapies are used together.
- Research indicates that normalizing tumor vasculature can improve immune cell infiltration.
Takeaway
This study looks at how two types of cancer treatments can work better together to help patients with digestive system cancers.
Methodology
This review summarizes recent advances in combining anti-angiogenic therapy and immune checkpoint inhibitors for treating digestive system cancers, focusing on clinical trials and preclinical studies.
Potential Biases
Potential biases may arise from the selective inclusion of studies and the evolving nature of cancer treatment.
Limitations
The review excludes failed and repetitive trials and is limited to anti-PD-1 and anti-PD-L1 therapies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website